A peripherally inserted central catheter offers a secure and reliable method of venous access for patients newly diagnosed with acute promyelocytic leukaemia

Abstract

Introduction:

Newly diagnosed acute promyelocytic leukaemia (APL) poses a significant bleeding risk. Current treatment guidelines advise against invasive procedures, such as central venous catheter placement. However, ensuring safe intravenous administration of both anti-leukaemic and supportive therapies is critical.

Methods:

This retrospective observational study examines real-world experiences with peripherally inserted central catheters (PICCs) in 84 newly diagnosed APL patients who received PICCs within the first week after diagnosis.

Results:

Of the 84 PICCs, 38 (45%) remained in situ for the full duration of treatment, while 36 (43%) were removed prematurely. The median PICC dwell time across the cohort was 139 days. No severe complications were reported following catheter implantation, and PICC use was not associated with mortality or permanent injury in any patient.

Conclusion:

These findings suggest that PICCs are a viable and safe option for venous access in APL patients, both during implantation and for extended use throughout treatment.